Trump agency nominations show pharma industry as divided as US
As US President-Elect Donald Trump, who will return to the White House in late January 2025, appoints healthcare agency heads,…
All articles by Fiona Barry
Fiona Barry
Fiona Barry is the Editor-in-Chief of GlobalData PharmSource’s editorial content. She previously worked as an investigative journalist reporting scoops on drug trials, contract pharma, rare diseases, and women’s health.
-
-
US Election: In close race, tiny Senate majority, not President, will hold power
How will the 2024 US election affect pharma? It all depends on who controls the House of Representatives and Senate,…
-
Novo to buy Catalent: the backlash begins
Novo Nordisk’s announcement this week of plans to buy the top contract development and manufacturing organization (CDMO) Catalent Inc (Somerset,…
-
Catalent CEO drops FY2023 revenue forecast by $450m after “disappointing” quarter
Catalent’s (Somerset, NJ, US) CEO has admitted to the company’s “disappointing” and “poor performance” over the past quarter, and dropped…
-
Build API facilities in Central and Eastern Europe to fix drug shortages, says report
An EU study claims that building more API facilities in Central and Eastern Europe could help solve drug shortages and…
-
FDA $7bn plans for 2024: disclose contract manufacturers, restart Cancer Moonshot
The US FDA has revealed its detailed budget proposal for FY2024, which would require pharma companies to name their active…
-
CMO Moves: Regulatory catalysts for drug manufacturing – March 2023
The biotech industry is currently undergoing a wider financial upheaval after the collapse of Silicon Valley Bank (SVB), which was…
-
CMO Moves: Regulatory catalysts for drug manufacturing- February
Manufacturing a drug therapy usually involves several different stakeholders. Contract manufacturing organizations (CMOs) not only produce the active pharmaceutical ingredient…
-
Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The…
-
FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan
FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San…